We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
58 hedge funds and large institutions have $72.5M invested in Crescent Biopharma in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 22 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
14% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $931K
0.11% less ownership
Funds ownership: 0.71% → 0.61% (-0.11%)
26% less funds holding
Funds holding: 78 → 58 (-20)
32% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 22
34% less capital invested
Capital invested by funds: $110M → $72.5M (-$37.8M)
69% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 29
Holders
58
Holders Change
-20
Holders Change %
-25.64%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
15
Reduced
22
Closed
29
Calls
$1.06M
Puts
$931K
Net Calls
+$132K
Net Calls Change
+$364K
Top Buyers
| 1 |
Millennium Management
New York
|
+$1.62M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$780K |
| 3 |
E
Ergoteles
New York
|
+$409K |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$346K |
| 5 |
Renaissance Technologies
New York
|
+$334K |
Top Sellers
| 1 |
BlackRock
New York
|
-$4.93M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.19M |
| 3 |
Two Sigma Investments
New York
|
-$1.63M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.3M |
| 5 |
SCM
Sio Capital Management
New York
|
-$1.07M |
